Scientists at the University of California have developed a drug that could provide a new treatment for metabolic dysfunction-associated steatohepatitis (MASH). 

This severe type of fatty liver disease is associated with obesity and type 2 diabetes and can progress to cirrhosis, liver failure, or liver cancer.